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Abstract 
Protection against SARS-CoV-2 and SARS-related zoonotic coronaviruses with pandemic 
potential is urgently needed. To evaluate immunization strategies, we made nanoparticles 
displaying the receptor-binding domain (RBD) of only SARS-CoV-2 (homotypic nanoparticles) or 
co-displaying the SARS-CoV-2 RBD along with RBDs from animal betacoronaviruses that 
represent threats to humans (mosaic nanoparticles; 4-8 distinct RBDs). Mice immunized with 
RBD-nanoparticles, but not soluble antigen, elicited cross-reactive antibody binding and 
neutralization responses, confirming increased immunogenicity from multimerization. Mosaic-
RBD-nanoparticles elicited antibodies with superior cross-reactive recognition of heterologous 
RBDs compared to sera from immunizations with homotypic SARS-CoV-2–RBD-nanoparticles or 
antibodies from COVID-19 convalescent human plasmas. Moreover, sera from mosaic-RBD–
immunized mice neutralized heterologous pseudotyped coronaviruses equivalently or better after 
priming than sera from homotypic SARS-CoV-2–RBD-nanoparticle immunizations, demonstrating 
no loss of immunogenicity against any particular RBD resulting from co-display. Thus, a single 
immunization with mosaic-RBD-nanoparticles provides a potential strategy to simultaneously 
protect against SARS-CoV-2 and emerging zoonotic coronaviruses. 
 
 
SARS-CoV-2, a newly-emergent betacoronavirus, resulted in a global pandemic in 2020, infecting 
millions and causing the respiratory disease COVID-19 (1, 2). Two other zoonotic 
betacoronaviruses, SARS-CoV and MERS-CoV, also resulted in outbreaks within the last 20 
years (3). All three viruses presumably originated in bats (4), with SARS-CoV and MERS-CoV 
adapting to intermediary animal hosts before jumping to humans. SARS-like viruses circulate in 
bats and serological surveillance of people living near caves where bats carry diverse 
coronaviruses demonstrated direct transmission of SARS-like viruses with pandemic potential (5), 
suggesting a pan-coronavirus vaccine is needed to protect against future outbreaks and 
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pandemics. In particular, the bat WIV1 and SHC014 strains are thought to represent an ongoing 
threat to humans (6, 7). 
 
Most current SARS-CoV-2 vaccine candidates include the spike trimer (S), the viral protein that 
mediates target cell entry after one or more of its receptor-binding domains (RBDs; S1B domains) 
adopt an “up” position to bind a host receptor (Fig. 1A). The RBDs of human coronaviruses SARS-
CoV-2, SARS-CoV, HCoV-NL63, and related animal coronaviruses (WIV1 and SCH014) utilize 
angiotensin-converting enzyme 2 (ACE2) as their host receptor (1, 8, 9), while other 
coronaviruses use receptors such as dipeptidyl peptidase 4 (10) or sialic acids (11, 12). 
Consistent with its function in viral entry, S is the primary target of neutralizing antibodies (13-22), 
with many targeting the RBD (14-18, 21-26). 
 
Multivalent display of antigen enhances B-cell responses and can provide longer-lasting immunity 
than monovalent antigens (27, 28), thus protein-based vaccine candidates often involve a 
nanoparticle that enables antigen multimerization. Many nanoparticles and coupling strategies 
have been explored for vaccine design (29), with a “plug and display” strategy being especially 
useful (30, 31). In this approach, SpyCatcher proteins fused to subunits of a virus-like particle 
form spontaneous isopeptide bonds to purified antigens tagged with a 13-residue SpyTag (29-
32). The SpyCatcher-SpyTag system was used to prepare multimerized SARS-CoV-2 RBD or S 
trimer that elicited high titers of neutralizing antibodies (33, 34). Although promising for protection 
against SARS-CoV-2, coronavirus reservoirs in bats suggest future cross-species transmission 
(6, 7, 35), necessitating a vaccine that protects against emerging coronaviruses as well as SARS-
CoV-2. Here we prepared SpyCatcher003-mi3 nanoparticles (31, 36) simultaneously displaying 
SpyTagged RBDs from human and animal coronaviruses to evaluate whether mosaic particles 
can elicit cross-reactive antibody responses, as previously demonstrated for influenza head 
domain mosaic particles (37). We show that mice immunized with homotypic or mosaic 
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nanoparticles produced broad binding and neutralizing responses, in contrast to plasma 
antibodies elicited in humans by SARS-CoV-2 infection. Moreover, mosaic nanoparticles showed 
enhanced heterologous binding and neutralization properties against human and bat  SARS-like 
betacoronaviruses (sarbecoviruses) compared with homotypic SARS-CoV-2 nanoparticles.  
 
We used a study of sarbecovirus RBD receptor usage and cell tropism (38) to guide our choice 
of RBDs for co-display on mosaic particles. From 29 RBDs that were classified into distinct clades 
(clades 1, 2, 1/2, and 3) (38), we identified diverse RBDs from SARS-CoV, WIV1, and SHC014 
(clade 1), SARS-CoV-2 (clade 1/2), Rs4081, Yunnan 2011 (Yun11), and Rf1 (clade 2), and BM48-
31 (clade 3), of which SARS-CoV-2 and SARS-CoV are human coronaviruses and the rest are 
bat viruses originating in China or Bulgaria (BM48-31). We also included RBDs from the GX 
pangolin clade 1/2 coronavirus (referred to here as pang17) (39), RaTG13, the bat clade 1/2 virus 
most closely related to SARS-CoV-2 (40), RmYN02, a clade 2 bat virus from China (41), and 
BtKY72, a Kenyan bat clade 3 virus (42). Mapping of the sequence conservation across selected 
RBDs showed varying degrees of sequence identity (68-95%), with highest sequence variability 
in the ACE2 receptor-binding motif (Fig. 1A-D; fig. S1). We chose 8 of the 12 RBDs for making 
three types of mosaic nanoparticles: mosaic-4a (coupled to SARS-2, RaTG13, SHC014, and 
Rs4081 RBDs), mosaic-4b (coupled to pang17, RmYN02, RF1, and WIV1 RBDs), and mosaic-8 
(coupled to all eight RBDs), and compared them with homotypic mi3 particles constructed from 
SARS-CoV-2 RBD alone (homotypic SARS-2). RBDs from SARS, Yun11, BM-4831, and BtKY72, 
which were not coupled to mosaic particles, were used to evaluate sera for cross-reactive 
responses.  
 
SpyTag003-RBDs were coupled to SpyCatcher003-mi3 (60 potential conjugation sites) (36, 43) 
to make homotypic and mosaic nanoparticles (Fig 2A). Particles were purified by size exclusion 
chromatography (SEC) and analyzed by SDS-PAGE, revealing monodisperse SEC profiles and 
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nearly 100% conjugation (Fig. 2B,C). Representative RBDs were conjugated to SpyCatcher003-
mi3 with similar or identical efficiencies (fig. S2), suggesting that mosaic particles contained 
approximately equimolar mixtures of different RBDs. 
 
We immunized mice with either soluble SARS-CoV-2 spike trimer (SARS-2 S), nanoparticles 
displaying only SARS-2 RBD (homotypic SARS-2), nanoparticles co-displaying RBDs (mosaic-
4a, mosaic-4b, mosaic-8), or unconjugated nanoparticles (mi3). IgG responses were evaluated 
after prime or boost immunizations (Fig. 3A) by ELISA against SARS-2 S (Fig. 3B) or a panel of 
RBDs (Fig. 3C-F; fig. S3). Sera from unconjugated nanoparticle-immunized animals (black in Fig. 
3, fig. S3) showed no responses above background. Anti-SARS-2 S trimer and anti-SARS-2 RBD 
serum responses were similar (Fig. 3B,C), demonstrating that antibodies elicited against RBDs 
can access their epitopes on SARS-2 S trimer. We also conducted in vitro neutralization assays 
using pseudotyped viruses for strains known to infect 293TACE2 target cells (SARS-CoV-2, SARS, 
WIV1 and SHC104). Neutralization and ELISA titers were significantly correlated (fig. S4), thus 
suggesting ELISAs are predictive of neutralization results when pseudotyped neutralization 
assays were not possible due to unknown viral entry receptor usage.  
 
Mice immunized with soluble SARS-2 S trimer (brown bars) showed no binding or neutralization 
except for autologous responses against SARS-2 after boosting (Fig. 3C-F). By contrast, sera 
from RBD-nanoparticle–immunized animals (red, green, yellow, and blue bars) exhibited binding 
to all RBDs (Fig. 3C-F; fig. S3A) and neutralization against all four strains after boosting (Fig. 3C-
E), consistent with increased immunogenicities of multimerized antigen on nanoparticles versus 
soluble antigen (27, 28). Homotypic SARS-2 nanoparticles, but not soluble SARS-2 trimer, 
induced heterologous responses to zoonotic RBDs and neutralization of heterologous 
coronaviruses (Fig. 3D-F). To address whether co-display of SARS-2 RBD along with other RBDs 
on mosaic-4a and mosaic-8 versus homotypic display of SARS-2 RBD (homotypic SARS-2) 
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diminished anti-SARS-2 responses, we compared SARS-2–specific ELISA and neutralization 
titers for mosaic versus homotypic immunizations (Fig. 3C): there were no significant differences 
in IgG anti-SARS-2 titers for animals immunized with homotypic (red in Fig. 3C) versus mosaic 
nanoparticles (green and blue in Fig. 3C). Thus there was no advantage of immunization with a 
homotypic RBD-nanoparticle versus a mosaic-nanoparticle that included SARS-2 RBD in terms 
of the magnitude of immune responses against SARS-2.  
 
We next compared serum responses against matched RBDs (RBDs present on an injected 
nanoparticle; gray horizontal shading) versus mismatched RBDs (RBDs not present on injected 
nanoparticle; red horizontal shading) (Fig. 3; fig. S3). Although SARS-2 RBD was not presented 
on mosaic-4b, antibody titers elicited by mosaic-4b immunization (yellow) were not significantly 
different than titers elicited by matched nanoparticle immunizations (homotypic SARS-2 (red), 
mosaic-4a (green), and mosaic-8 (blue)), and sera from boosted mosaic-4b–immunized mice 
neutralized SARS-2 pseudovirus (Fig. 3C). In other matched versus mismatched comparisons, 
sera showed binding and neutralization of SHC014 and WIV1 regardless of whether these RBDs 
were included on the injected nanoparticle (Fig. 3D), underscoring sharing of common epitopes 
among RBDs (Fig. 1A). Demonstrating advantages of mosaic versus homotypic SARS-2 
nanoparticles, sera from mosaic-8–immunized mice bound SHC014 and WIV1 RBDs significantly 
better after the prime than sera from homotypic SARS-2–immunized mice and retained better 
binding to SHC014 RBD after boosting (Fig. 3D). Moreover, mosaic-8–immunized and boosted 
sera were 7-44–fold more potent than sera from homotypic SARS-2–immunized animals in 
neutralizing SHC014 and WIV1 (Fig. 3D). Mosaic-8 included SHC014 and WIV1 RBDs, again 
suggesting that combining RBDs on a mosaic nanoparticle does not diminish the immune 
response against a particular RBD, as also suggested by ELISAs against Rs4081 and RaTG13 
(fig. S3A,B). 
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To address whether RBD-nanoparticles elicited antibodies against totally mismatched strains, we 
evaluated sera for binding to SARS, Yun11, BM-4831, and BtKY72 RBDs (Fig. 3E,F) and 
neutralization of SARS (Fig. 3E). Against these RBDs, we found significantly higher and more 
cross-reactive antibody responses for mosaic immunizations compared with homotypic SARS-2 
immunizations: e.g., mosaic-8–primed and boosted animals showed significantly higher titers 
against SARS RBD than sera from homotypic SARS-2–immunized mice (Fig. 3E). After the prime, 
sera from the homotypic SARS-2–immunized animals did not neutralize SARS, whereas the 
mosaic-4b and mosaic-8 sera were neutralizing (Fig. 3E), perhaps facilitated by these 
nanoparticles including WIV1 RBD, which is related by 95% amino acid identity to SARS RBD 
(Fig. 1D). After boosting, SARS-2 and mosaic-4a sera were also neutralizing, although titers were 
~4-fold lower than for mosaic-8–immunized animals (Fig. 3E). ELISA titers against other 
mismatched RBDs (Yun11, BM-4831, BtKY72) were significantly higher for sera collected after 
mosaic-8 priming compared to sera from homotypic SARS-2 priming, and heightened binding was 
retained after boosting (Fig. 3F). Thus mosaic nanoparticles, particularly mosaic-8, induce higher 
antibody titers against mismatched RBDs than homotypic SARS-2 nanoparticles, again favoring 
the co-display approach for inducing broader anti-coronavirus responses, especially after a single 
prime. 
 
We investigated the potential for cross-reactive recognition using flow cytometry to ask whether 
B-cell receptors on IgG+ splenic B-cells from RBD-nanoparticle–boosted animals could 
simultaneously recognize RBDs from SARS-2 and Rs4081 (related by 70% sequence identity) (Fig. 
1D; fig. S5). Whereas control animals were negative, all other groups showed B-cells that 
recognized SARS-2 and Rs4081 RBDs simultaneously, suggesting the existence of antibodies 
that cross-react with both RBDs (fig. S5E). 
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To compare antibodies elicited by RBD-nanoparticle immunization to antibodies elicited by SARS-
CoV-2 infection, we repeated ELISAs against the RBD panel using IgGs from COVID-19 plasma 
donors (44) (Fig. 4). Most of the convalescent plasmas showed detectable binding to SARS-2 
RBD (Fig. 4A). However, binding to other sarbecovirus RBDs (RaTG13, SHC014, WIV1, Rs4081 
and BM-4831) was significantly weaker than binding to SARS 2 RBD, with many human plasma 
IgGs showing no binding above background (Fig. 4B-G). In addition, although convalescent 
plasma IgGs neutralized SARS-CoV-2 pseudoviruses, they showed weak or no neutralization of 
SARS, SHC014, or WIV1 pseudoviruses (Fig. 4H). These results are consistent with little to no 
cross-reactive recognition of RBDs from zoonotic coronavirus strains resulting from SARS-CoV-
2 infection in humans. 
 
In conclusion, we confirmed that multimerization of RBDs on nanoparticles enhances 
immunogenicity compared with soluble antigen (33, 45) and further showed that homotypic 
SARS-2 nanoparticle immunization produced IgG responses that bound zoonotic RBDs and 
neutralized heterologous coronaviruses after boosting. By contrast, soluble SARS-2 S 
immunization and natural infection with SARS-CoV-2 resulted in weak or no heterologous 
responses in plasmas. Co-display of SARS-2 RBD along with diverse RBDs on mosaic 
nanoparticles showed no disadvantages for eliciting neutralizing antibodies against SARS-CoV-
2 compared with homotypic SARS-2 nanoparticles, suggesting mosaic nanoparticles as a 
candidate vaccine to protect against COVID-19. Furthermore, compared with homotypic SARS-2 
RBD particles, the mosaic co-display strategy demonstrated advantages for eliciting neutralizing 
antibodies against zoonotic sarbecoviruses, thus potentially also providing protection against 
emerging coronaviruses with human spillover potential. Importantly, neutralization of matched 
and mismatched strains was observed after mosaic priming, suggesting a single injection of a 
mosaic-RBD nanoparticle might be sufficient in a vaccine, greatly simplifying large-scale 
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immunizations. Since COVID-19 convalescent plasmas showed little to no recognition of 
coronavirus RBDs other than SARS-CoV-2, COVD-19–induced immunity in humans may not 
protect against another emergent coronavirus. However, the mosaic nanoparticles described here 
could be used as described and/or easily adapted to present RBDs from newly-discovered 
zoonotic coronaviruses. Since these types of RBD-nanoparticles retain immunogenicity after 
lyophilization (33), they could be easily stored for widespread use. Thus this modular vaccine 
platform could provide protection from SARS-CoV-2 and potential future coronavirus pandemics 
resulting from emergent zoonotic sarbecoviruses. 
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Figure legends 
Figure 1. Properties of RBDs chosen for this study. (A) Left: Structure of SARS-CoV-2 S trimer 
(PDB 6VXX) with one RBD (dashed circle) in an “up” position. Middle and right: Sequence 
conservation of 12 RBDs calculated by the ConSurf Database (46) plotted on a surface 
representation of the RBD structure (PDB 7BZ5). Epitopes for representatives from defined 
classes of RBD-binding antibodies (class 1-class 4) (24) indicated by dashed lines. (B) Summary 
of properties of the viral strains from which the 12 sarbecovirus RBDs were derived. (C) 
Phylogenetic tree of human and selected other coronaviruses based on RBD protein sequences. 
(D) Heat map showing percent amino acid sequence identities between 12 sarbecovirus RBDs.  
 
Figure 2. Construction of RBD nanoparticles. (A) Left: SpyTagged RBDs were attached to 
SpyCatcher003-mi3 to make a homotypic particle and three mosaic particles. 10 of 60 potential 
coupling sites on mi3 are shown for clarity. (B) SEC profile showing separation of RBD 
nanoparticles and free RBD proteins. (C) Coomassie-stained SDS-PAGE of RBD-coupled 
nanoparticles, free RBD proteins, and uncoupled SpyCatcher003-mi3 particles (SC3-mi3). 
 
Figure 3. RBD nanoparticles induce cross-reactive IgG responses in immunized mice. Red and 
gray rectangles below ELISA and neutralization data represent mismatched strains (red; RBD 
from that strain was not present on the immunized particle) or matched strains (gray; RBD was 
present on the immunized particle). (A) Left: Immunization schedule. Adjuvant=AddaVax 
(Invivogen). Right: Key for immunizations; number of mice in each cohort is indicated. (B-F) Mice 
were immunized with soluble SARS-CoV-2 S trimer (SARS-2 S; brown bars), or the following 
nanoparticles: homotypic SARS-2 (red), mosaic-4a (green), mosaic-4b (yellow), mosaic-8 (blue), 
or unconjugated SpyCatcher003-mi3 (mi3; black). ELISA data from serum IgG responses to 
SARS-2 spike trimer (B) or RBDs (C-F) shown as area under the curve (AUC). For C-E, 
neutralization potencies are presented as half-maximal inhibitory dilutions (ID50 values) of sera 
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted December 1, 2020. ; https://doi.org/10.1101/2020.11.17.387092doi: bioRxiv preprint 
 12 
against the pseudoviruses from the indicated coronavirus strains. Dashed horizontal lines 
correspond to the lowest dilution representing the limit of detection. Each dot represents serum 
from one animal, with means and standard deviations for vaccinated cohorts represented by 
rectangles (mean) and horizontal lines (SD). Significant differences between groups linked by 
horizontal lines are indicated by asterisks and p-values. NS=not significant. (B-F) Neutralization 
and/or binding data for serum IgGs for recognition of (B) SARS-2 spike trimer, (C) SARS-2 RBD 
and SARS-2 pseudovirus, (D) SHC014 and WIV1 RBDs and corresponding pseudoviruses, (E) 
SARS RBD and SARS pseudovirus, (F) Yun 11, BM-4831, and BtKY72 RBDs.  
 
Figure 4. IgGs from convalescent COVID-19 plasma (18, 24) show little to no cross-reactive 
responses. (A-F) Plasma IgG responses were evaluated by ELISA (data shown as binding curves 
with plasma names (18) listed) against RBDs from (A) SARS-2, (B) RaTG13, (C) SHC014, (D) 
WIV1, (E) Rs4081, and (F) BM-4831. Data points are plotted as the mean and standard deviation 
of duplicate measurements. IOMA, an anti-HIV-1 IgG (47), was used as a control. (G) ELISA 
results from panels A-F presented as area under the curve (AUC), where each dot represents 
one plasma sample, with means and standard deviations represented by rectangles (mean) and 
horizontal lines (SD). Significant differences between groups linked by horizontal lines are 
indicated by asterisks and p-values. (H) IC50 values for pseudotyped neutralization assays using 
IgGs from COV7, COV21, and COV72 plasmas (18) (evaluated at top concentrations of 1500 
µg/mL) against the indicated strains. Mean=arithmetic mean IC50; SD=standard deviation.  
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted December 1, 2020. ; https://doi.org/10.1101/2020.11.17.387092doi: bioRxiv preprint 
 13 
 
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted December 1, 2020. ; https://doi.org/10.1101/2020.11.17.387092doi: bioRxiv preprint 
 14 
 
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted December 1, 2020. ; https://doi.org/10.1101/2020.11.17.387092doi: bioRxiv preprint 
 15  
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted December 1, 2020. ; https://doi.org/10.1101/2020.11.17.387092doi: bioRxiv preprint 
 16 
 
.CC-BY-NC-ND 4.0 International licenseavailable under a
(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprintthis version posted December 1, 2020. ; https://doi.org/10.1101/2020.11.17.387092doi: bioRxiv preprint 
 17 
Methods  
 
Phylogenetic tree. A sequence alignment of coronavirus RBD domains was made using Clustal 
Omega (48). A phylogenetic tree was calculated from this amino acid alignment using PhyML 3.0 
(49), and a figure of this tree was made using PRESTO (http://www. atgc-montpellier.fr/presto). 
 
Expression of RBD and S proteins. Mammalian expression vectors encoding the RBDs of 
SARS-CoV-2  (GenBank MN985325.1; S protein residues 319-539) and SARS-CoV S (GenBank 
AAP13441.1; residues 318-510) with an N-terminal human IL-2 or Mu phosphatase signal peptide 
were previously described (44). Expression vectors were constructed similarly for RBDs from the 
following other sarbecovirus strains: RaTG13-CoV (GenBank QHR63300; S protein residues 319-
541), SHC014-CoV (GenBank KC881005; residues 307-524), Rs4081-CoV (GenBank KY417143; 
S protein residues 310-515), pangolin17-CoV (GenBank QIA48632; residues 317-539), 
RmYN02-CoV (GSAID EPI_ISL_412977; residues 298-503), Rf1-CoV (GenBank DQ412042; 
residues 310-515), W1V1-CoV (GenBank KF367457; residues 307-528), Yun11-CoV (GenBank 
JX993988; residues 310-515), BM-4831-CoV (GenBank NC014470; residues 310-530), BtkY72-
CoV (GenBank KY352407; residues 309-530). Two versions of each RBD expression vector were 
made: one including a C-terminal hexahistidine tag (G-HHHHHH) and SpyTag003 
(RGVPHIVMVDAYKRYK) (43) (for coupling to SpyCatcher003-mi3) and one with only a 
hexahistidine tag (for ELISAs). Biotinylated SARS-CoV-2 and Rs4081 RBDs were produced by 
co-transfection of Avi/His-tagged RBD expression plasmids with an expression plasmid encoding 
an ER-directed BirA enzyme (kind gift of Michael Anaya, Caltech). RBD proteins were purified 
from transiently-transfected Expi293F cell (Gibco) supernatants by nickel affinity and size-
exclusion chromatography (44). Peak fractions corresponding to RBDs were identified by SDS-
PAGE and then pooled and stored at 4˚C. A trimeric SARS-CoV-2 ectodomain with 6P stabilizing 
mutations (50) was expressed and purified as described (24). To prepare fluorochrome-
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conjugated streptavidin-tetramerized RBDs, biotinylated SARS-2 and Rs4081 RBDs were 
incubated with streptavidin-APC (eBioscienceTM) and streptavidin-PE (ThermoFisher), 
respectively, overnight at 4oC at a 1:1 molar ratio of RBD to streptavidin subunit.  
 
Preparation of human plasma IgGs. Plasma samples collected from COVID-19 convalescent 
and healthy donors are described in (18). Human IgGs were isolated from heat-inactivated plasma 
samples using 5-mL HiTrap MabSelect SuRe columns (GE Healthcare Life Sciences) as 
described (24).  
 
Preparation of RBD-mi3 nanoparticles. SpyCatcher003-mi3 particles were prepared by 
purification from BL21 (DE3)-RIPL E coli (Agilent) transformed with a pET28a SpyCatcher003-
mi3 gene (including an N-terminal 6x-His tag) as described (51). Briefly, cell pellets from 
transformed bacterial were lysed with a cell disruptor in the presence of 2.0 mM PMSF (Sigma). 
Lysates were spun at 21,000xg for 30 min, filtered with a 0.2 µm filter, and mi3 particles were 
isolated by Ni-NTA chromatography using a pre-packed HisTrapTM HP column (GE Healthcare). 
Eluted particles were concentrated using an Amicon Ultra 15 mL 30K concentrator 
(MilliporeSigma) and purified by SEC using a HiLoad® 16/600 Superdex® 200 (GE Healthcare) 
column equilibrated with 25 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.02% NaN3 (TBS). SpyCatcher-
mi3 particles were stored at 4°C and used for conjugations for up to 1 month after filtering with a 
0.2 µm filter or spinning at 21,000xg for 10 min. 
 
Purified SpyCatcher003-mi3 was incubated with a 3-fold molar excess (RBD to mi3 subunit) of 
purified SpyTagged RBD (either a single RBD for making homotypic SARS-CoV-2 RBD particles 
or an equimolar mixture of four or eight RBDs for making mosaic particles) overnight at room 
temperature in TBS. Conjugated mi3 particle were separated from free RBDs by SEC on a 
Superose 6 10/300 column (GE Healthcare) equilibrated with PBS (20 mM sodium phosphate pH 
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7.5, 150 mM NaCl). Fractions corresponding to conjugated mi3 particles were collected and 
analyzed by SDS-PAGE. Concentrations of conjugated mi3 particles were determined using a 
Bio-Rad Protein Assay.  
 
Immunizations. Animal procedures and experiments were performed according to protocols 
approved by the IACUC. Experiments were done using 4-6 week old female Balb/c mice (Charles 
River Laboratories), with 5 animals each for cohorts immunized with soluble SARS-CoV-2 S or 
SpyCatcher003-mi3, and 10 animals each for remaining cohorts (Fig 3A). Immunizations were 
carried out with intraperitoneal (ip) injections of either 5 µg of conjugated RBD (calculated as the 
mass of the RBD, assuming 100% efficiency of conjugation to SpyCatcher003-mi3), 5 µg of 
soluble SARS-CoV-2 S, or 6 µg of unconjugated SpyCatcher003-mi3, in 100 µL of 50% v/v 
AddaVaxTM adjuvant (Invivogen). Animals were boosted 4 weeks after the prime with the same 
quantity of antigen in adjuvant. Animals were bled every 2 weeks via tail veins, and then 
euthanized 8 weeks after the prime (Day 56, 57) and bled through cardiac puncture. Blood 
samples were allowed to clot at room temperature in MiniCollect® Serum and Plasma Tubes 
(Greiner), and serum was harvested, preserved in liquid nitrogen, and stored at -80˚C until use.  
 
Sera for ELISAs were collected at Day 14 (Prime) and Day 42 (Boost). Sera for neutralization 
assays were collected at Day 28 (Prime) and Day 56 (Boost) (Fig. 3, fig. S3). 
 
ELISAs. 10 µg/ml of a purified RBD (not SpyTagged) in 0.1 M NaHCO3 pH 9.8 was coated onto 
Nunc® MaxiSorp™ 384-well plates (Sigma) and stored overnight at 4oC. Plates were washed 
with Tris-buffered saline with 0.1% Tween 20 (TBS-T) after blocking with 3% bovine serum 
albumin (BSA) in TBS-T for 1 hr at room temperature. Mouse serum was diluted 1:100 and then 
serially diluted by 4-fold with TBS-T/3% BSA and added to plates for 3 hr at room temperature. A 
1:50,000 dilution of secondary HRP-conjugated goat anti-mouse IgG (Abcam) was added after 
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washing for 1 hr at room temperature. Plates were developed using SuperSignal™ ELISA Femto 
Maximum Sensitivity Substrate (ThermoFisher) and read at 425 nm. Curves were plotted and 
integrated to obtain the area under the curve (AUC) using Graphpad Prism 8.3 assuming a one-
site binding model with a Hill coefficient (Fig. 3; fig. S3). We also calculated EC50s and endpoint 
titers, which were determined using the dilution that was at or below the mean + 2 x the standard 
deviation of the plate control (no primary serum added) for ELISA binding data (fig. S3C,D). AUC 
calculations were used as they better capture changes in maximum binding (52). Statistical 
significance of titer differences between groups were calculated using Tukey’s multiple 
comparison test using Graphpad Prism 8.3.  
 
Neutralization assays. SARS-CoV-2, SARS, WIV1, and SHC014 pseudoviruses based on HIV 
lentiviral particles were prepared as described (18, 53) using genes encoding S protein 
sequences lacking C-terminal residues in the cytoplasmic tail: 21 amino acid deletions for SARS-
CoV-2, WIV1, and SHC014 and a 19 amino acid deletion for SARS-CoV. For neutralization 
assays, four-fold serially diluted sera from immunized mice were incubated with a pseudotyped 
virus for 1 hour at 37˚C. After incubation with 293TACE2 target cells for 48 hours at 37˚C, cells were 
washed twice with phosphate-buffered saline (PBS) and lysed with Luciferase Cell Culture Lysis 
5x reagent (Promega). NanoLuc Luciferase activity in lysates was measured using the Nano-Glo 
Luciferase Assay System (Promega). Relative luminescence units (RLUs) were normalized to 
values derived from cells infected with pseudotyped virus in the absence of serum. Half-maximal 
inhibitory dilutions (ID50 values) were determined using 4-parameter nonlinear regression in 
AntibodyDatabase (54). Statistical significance of titer differences between groups were 
calculated using Tukey’s multiple comparison test of ID50s converted to log10 scale using 
Graphpad Prism 8.3. 
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Statistical Analysis. Comparisons between groups for ELISAs and neutralization assays were 
calculated with one-way analysis of variance (ANOVA) using Tukey’s post hoc test in Prism 9.0 
(Graphpad). For correlation analysis between ELISA and neutralization titers, significance (p), 
Spearman coefficients (rs), and linear plots were calculated using Prism 9.0 (Graphpad). 
Differences were considered significant when p values were less than 0.05. Exact p values are in 
relevant figure near each corresponding line, with asterisks denoting level of significance (* 
denotes 0.01<p<0.05, ** denotes 0.001<p<0.01, *** denotes 0.0001<p<0.001, and **** denotes 
p<0.0001). 
 
Flow cytometry. B-cell analysis using flow cytometry was carried out as described (51). Briefly, 
single-cell suspensions were prepared from mouse spleens using mechanical dissociation, and 
red blood cells were removed using ACK lysing buffer (Gibco). The white blood cell preparation 
was enriched for IgG+ B-cells using the negative selection protocol in a mouse memory B-cell 
isolation kit (Miltenyi). The following commercial reagents were used to stain enriched splenocytes: 
CD4-APC-eFluor 780 (clone: RM4-5), F4/80-APC-eFluor 780 (clone: BM8), CD8a-APC-eFluor 
780 (clone: 53-6.7), Ly-6G-APC-eFluor 780 (clone: RB6-8C5), IgM- APC-eFluor 780 (clone: II/41) 
(Thermo Fisher Scientific), CD19-FITC (clone: 6D5) (Biolegend), IgG1 BV421 (clone: X40) and 
IgG2 BV421 (clone: R19-15) (BD Bioscience). SARS-2 RBD-APC and Rs4081 RBD-PE for used 
to identify antigen-specific B-cells. Cell viability was analyzed with Fixable Viability Stain 700 (BD 
Bioscience). Stained cells were analyzed with a SY3200 Cell Sorter (Sony) configured to detect 
6 fluorochromes. 2,000,000 events were collected per sample and analyzed via FlowJo software 
(TreeStar).  
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Supplementary Figure legends 
 
Figure S1. Alignment of RBD sequences used for making mosaic particles. Sequences shown 
are for the RBDs of SARS-CoV-2 (SARS-2, GenBank: MN985325.1), RaTG13 (QHR63300), 
SHC014 (RsSHC014, KC881005), Rs4081 (KY417143), PCoV_GX-P5L (pang17) (QIA48632), 
RmYN02 (GSAID EPI_ISL_412977), Rf1 (DQ412042), WIV1 (KF367457), SARS-CoV 
(AAP13441.1), Yun11 (Cp/Yunnan2011, JX993988), BM-4831 (BM48-31/BGR/2008, NC014470), 
and BtKY72 (KY352407). 
 
Figure S2. RBDs from the eight sarbecovirus S proteins conjugate equivalently to 
SpyCatcher003-mi3, suggesting a statistical mixture of RBDs on mosaic particles. (A) SEC 
profiles showing separation of RBD nanoparticles and free RBD proteins. (B) Coomassie-stained 
SDS-PAGE of RBD-coupled nanoparticles, free RBD proteins, and uncoupled SpyCatcher003-
mi3 particles (SC3-mi3). 
 
Figure S3. Day 14 serum IgG responses to RBDs evaluated by ELISA shown as area under the 
curve (AUC) from mice immunized with soluble SARS-CoV-2 S trimers (SARS-2 S) or RBDs on 
nanoparticles (homotypic SARS-2, mosaic-4a, mosaic-4b, mosaic-8, or unconjugated 
SpyCatcher003-mi3 (mi3)). Each dot represents serum from one animal, with means and 
standard deviations represented by rectangles (mean) and horizontal lines (SD). RBDs from 
strains that were not present on an immunized particle or were present on an immunized particle 
are indicated by red and gray rectangles, respectively, below the ELISA data. Significant 
differences between groups linked by horizontal lines are indicated by asterisks and p-values. 
NS=not significant. (A,B) Binding of serum IgGs to (A) Rs4081 and (B) RaTG13 RBDs. (C,D) 
Comparison of ELISA data for serum binding to selected RBDs presented as AUC, endpoint titers, 
midpoint titers, or binding curves. Day 14 serum IgG responses to (C) SARS-2 or (D) SARS RBDs 
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evaluated by ELISA shown as AUC (left), endpoint titers (middle left), midpoint (EC50) titers 
(middle right), or binding curves (right). For AUC, each dot represents serum from one animal, 
with means and standard deviations represented by rectangles (mean) and horizontal lines (SD). 
For endpoint and midpoint titers, each dot represents serum from one animal, with geometric 
means and geometric standard deviations represented by rectangles (mean) and horizontal lines 
(SD). Binding curves are shown with data points representing the mean and SD of duplicate 
measurements fit to a binding model (see Methods) for animals immunized with mosaic-8 and 
homotypic SARS-2.  
 
Figure S4. Correlation of ELISA and neutralization titers. Spearman correlation coefficients (rS) 
and p-values shown for graphs of anti-RBD ELISA titers (AUC) versus pseudovirus neutralization 
ID50 values; significance indicated as asterisks. (A) SARS-2. (B) SARS. (C) SHC014. (D) WIV1.  
 
Figure S5. Antigen-specific IgG+ B-cell analysis of splenocytes isolated from animals immunized 
with mosaic-RBD nanoparticles. (A) Flow cytometry gating strategy for characterizing RBD-
specific IgG+ B-cells isolated from splenocytes. Anti-CD4, anti-CD8, anti-F4/80, anti-Ly6G, and 
anti-IgM were used in the dump to remove T-cells, macrophages, and IgM+ B-cells. Antigen-
specific IgG+ B-cells were isolated using labeled anti-CD19 and anti-IgG antibodies, and probed 
for binding RBD with a pair of fluorophore-conjugated RBD tetramers (SARS-2 RBD and Rs4081 
RBD). (B) Complete flow cytometry analysis for antigen-specific IgG+ splenocytes isolated from 
animals immunized with mosaic-RBD particles. The 4-way gate shown for each animal separates 
each population of RBD single-positive and double-positive cells and was used for the % antigen-
specific populations shown in panels C-E. Q1 represents the Rs4081 RBD+ population, Q2 
represents the Rs4081 RBD+ / SARS-2 RBD+ population, Q3 represents the SARS-2 RBD+ 
population, and Q4 represents the RBD- population. (C-E) Percent single-positive (SP) and 
double-positive (DP) cells for the indicated groups. Significant differences between groups linked 
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by horizontal lines are indicated by asterisks and p-values. NS = not significant. (C) Percent 
SARS-2 RBD+ B-cells within the IgG+ B-cell population. (D) Percent Rs4081 RBD+ B-cells within 
the IgG+ B-cell population. (E) Percent SARS-2 RBD+ / Rs4081 RBD+ B-cells within the IgG+ B-
cell population. 
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